Headlines about XOMA (NASDAQ:XOMA) have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. XOMA earned a news impact score of 0.13 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 48.1989282316335 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
XOMA has been the topic of several research analyst reports. HC Wainwright set a $49.00 target price on XOMA and gave the stock a “buy” rating in a research note on Monday, April 30th. Zacks Investment Research downgraded XOMA from a “hold” rating to a “strong sell” rating in a research note on Thursday, May 10th. Cowen restated a “hold” rating on shares of XOMA in a research note on Thursday, May 10th. TheStreet upgraded XOMA from a “d” rating to a “c-” rating in a research note on Tuesday, June 12th. Finally, Wedbush restated an “outperform” rating and set a $33.00 target price on shares of XOMA in a research note on Wednesday, August 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. XOMA presently has a consensus rating of “Hold” and a consensus price target of $31.32.
XOMA stock traded up $0.09 on Monday, hitting $17.08. 2,502 shares of the company’s stock were exchanged, compared to its average volume of 120,003. XOMA has a 12-month low of $9.80 and a 12-month high of $37.25. The company has a debt-to-equity ratio of 3.06, a current ratio of 12.46 and a quick ratio of 12.46. The company has a market cap of $142.50 million, a price-to-earnings ratio of 17.43 and a beta of 2.64.
XOMA Company Profile
XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.
See Also: How Do You Make Money With Penny Stocks?
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.